lol
It will only be important if the Lympro identifies people who will respond to p16.
That is, if p16 works in humans. We will find that out in about ten years.
IOW, given that the administration of p16 will be very expensive, if for some reason, Lympro identifies those who will do well, then there will be reason to give the test.
In that case, it would be like the apo e gene which identifies those who may get AD.
Once again, my dad went into assisted living just today with ad. He would not benefit from that test, nor would I or any of my siblings. I am sure.
As far as the fda rules are concerned, this test is not life altering nor is it for a rare disease.
As I said, I have enough to stuff into my head, but you just can't ignore this, this new FDA reg is good in general. Whether or not it pertains to Lympro remains to be seen.
You would think that nothing happened on Thursday, based on this board. It did happen, and it was relevant, and it was negative, again.
News 
Market Data 
Discover 
